Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development	$ 5,656	$ 3,688	$ 12,501	$ 6,979
General and administrative	2,043	1,320	5,686	2,753
In-process research and development assets acquired				32,057
Total operating expenses	7,699	5,008	18,187	41,789
Loss from operations	(7,699)	(5,008)	(18,187)	(41,789)
Other income (expense), net	(52)	(92)	(180)	(122)
Net loss	$ (7,751)	$ (5,100)	$ (18,367)	$ (41,911)
Net loss per share - basic and diluted	$ (0.54)	$ (0.45)	$ (1.34)	$ (7.36)
Weighted average shares outstanding, basic and diluted	14,241,220	11,209,052	13,702,727	5,691,587